Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Accounts Payables (2019 - 2025)

Historic Accounts Payables for IDEAYA Biosciences (IDYA) over the last 7 years, with Q4 2025 value amounting to $17.6 million.

  • IDEAYA Biosciences' Accounts Payables rose 1402.63% to $17.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $17.6 million, marking a year-over-year increase of 1402.63%. This contributed to the annual value of $17.6 million for FY2025, which is 1402.63% up from last year.
  • Latest data reveals that IDEAYA Biosciences reported Accounts Payables of $17.6 million as of Q4 2025, which was up 1402.63% from $18.4 million recorded in Q3 2025.
  • In the past 5 years, IDEAYA Biosciences' Accounts Payables registered a high of $18.4 million during Q3 2025, and its lowest value of $1.3 million during Q1 2021.
  • Moreover, its 5-year median value for Accounts Payables was $5.5 million (2023), whereas its average is $8.3 million.
  • Over the last 5 years, IDEAYA Biosciences' Accounts Payables had its largest YoY gain of 18030.21% in 2025, and its largest YoY loss of 871.21% in 2025.
  • IDEAYA Biosciences' Accounts Payables (Quarter) stood at $2.1 million in 2021, then skyrocketed by 103.81% to $4.3 million in 2022, then soared by 54.16% to $6.6 million in 2023, then soared by 133.72% to $15.4 million in 2024, then rose by 14.03% to $17.6 million in 2025.
  • Its Accounts Payables stands at $17.6 million for Q4 2025, versus $18.4 million for Q3 2025 and $17.3 million for Q2 2025.